Hosted on MSN11mon
Ionis Pharmaceuticals to pursue approval of FCS drug after Phase III winIonis will be pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS. Olezarsen is an RNA-targeted investigational ligand conjugated antisense (LICA ...
AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. While preparing to go head to head in a rare disease market, the companies have signed up ...
Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended for familial chylomicronaemia syndrome (FCS) and ...
Hosted on MSN1mon
Why Ionis Pharmaceuticals, Inc. (IONS) Is Among the Best Healthcare Stocks To Buy According to AnalystsIn this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...
– Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license ...
Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: A live ...
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal Ionis grants Ono global rights to sapablursen for polycythemia vera in a ...
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.
CARLSBAD, Calif., March 26, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback